Objective
Seeks long-term capital appreciation.
Overview
A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.
The Health-Care Revolution
The health-care sector is undergoing dramatic changes that will impact everything from the drugs we take to the way patients’ medical records are shared. Aging demographics globally and rising prosperity in emerging-market nations will drive even greater demand for lifesaving drugs, innovative procedures, and disruptive medical technology.
Pipeline to Innovation
With innovation and breakthroughs taking place across the globe, the Fund uses a broadly diversified, global approach that seeks to identify companies with the greatest opportunities in areas including biotechnology, medical technology, health services, and pharmaceuticals.
Backed by Size, Scale, and Experience
Wellington Management, the Fund’s sub-adviser, is one of the largest managers of health care stocks in the world. The portfolio managers on the Fund average 26 years of experience.
|
Average Annual Total Returns % (as of 12/31/2019)
|
|||||
| 1YR | 5YR | 10YR | SI | ||
|---|---|---|---|---|---|
| Hartford Healthcare I | 33.69 | 10.42 | 15.76 | 12.03 | |
| Benchmark | 20.87 | 10.69 | 15.17 | --- | |
| Morningstar Health Category | 26.10 | 8.58 | 15.05 | --- | |
|
Average Annual Total Returns % (as of 12/31/2019)
|
|||||
| 1YR | 5YR | 10YR | SI | ||
|---|---|---|---|---|---|
| Hartford Healthcare I | 33.69 | 10.42 | 15.76 | 12.03 | |
| Benchmark | 20.87 | 10.69 | 15.17 | --- | |
| Morningstar Health Category | 26.10 | 8.58 | 15.05 | --- | |
Class I-share performance prior to its inception date reflects Class A-share performance (excluding sales charges) and operating expenses. SI performance is calculated from 5/1/00.
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.
Growth of $10,000 (I-Share)
(as of 12/31/2019)
(as of 12/31/2019)
-
Overall
:
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 4 stars, and 10-Year, 4 stars, rated against 135, 135, 125 and 102 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures. Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2020 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.:
- 135 Products | Health Category
Morningstar Analyst Rating
Morningstar awarded the Fund a Bronze analyst rating on 2/25/191
| Fund | BENCHMARK | |
|---|---|---|
| 2019 | 33.69 | 20.87 |
| 2018 | -2.74 | 6.71 |
| 2017 | 21.94 | 22.47 |
| 2016 | -8.33 | -2.05 |
| 2015 | 12.97 | 7.41 |
| 2014 | 26.80 | 24.79 |
| 2013 | 49.95 | 42.19 |
| 2012 | 20.14 | 18.35 |
| 2011 | 8.03 | 11.88 |
| 2010 | 6.69 | 5.20 |
Excludes sales charges. If sales charges and taxes had been included, the value would have been lower.
CharacteristicsAllocations, exposures and holdings are subject to change. Percentages may be rounded.
| As of Date | 12/31/2019 |
| Net Assets | $1.4 billion |
| # of Holdings | 104 |
| % in Equities | 99 |
| % in Foreign Equities | 18 |
| Beta (3 year) | 1.09 |
| R Squared (3 year) | 0.85 |
| Standard Deviation | 15.54% |
| Turnover (12/31/2019) | 42% |
| Active Share | 58% |
| Fund | S&P Composite 1500 Health Care Index | |
|---|---|---|
| Price/Earnings | 36.6x | 16.3x |
| Price/Book | 4.8x | 5.3x |
| EPS Growth Rate | 12.7% | 10.1% |
| Return on Equity | 0.5% | 20.0% |
| Asset Weighted Market Cap (billions) | $72.8 | $137.3 |
| Median Market Cap (billions) | $5.1 | $4.0 |
| Fund | |
|---|---|
| Alpha (5 Year) | -1.23 |
| Down Capture (5 Year) | 116.84 |
| Information Ratio (5 Year) | -0.04 |
| Sharpe Ratio (5 Year) | 0.62 |
| Up Capture (5 Year) | 108.93 |
| Fund | |
|---|---|
| Less than $2 billion | 12 |
| $2 billion - $5 billion | 13 |
| $5 billion - $10 billion | 7 |
| Greater than $10 billion | 69 |
| Not Classified | 0 |
Regional Exposure (%)
| label | value |
|---|---|
| North America | 82 |
| Europe | 11 |
| Japan | 4 |
| Emerging Markets | 3 |
| Middle East/Developed | 1 |
| label | value |
|---|---|
| North America | 83 |
| Europe | 10 |
| Japan | 4 |
| Emerging Markets | 2 |
| Middle East/Developed | 1 |
Top Ten Holdings (%)
| label | percentageholding |
|---|---|
| Pfizer, Inc. | 5.45 |
| Abbott Laboratories | 4.49 |
| Bristol-Myers Squibb Co. | 4.36 |
| Medtronic plc | 4.12 |
| Thermo Fisher Scientific, Inc. | 3.60 |
| Eli Lilly & Co. | 3.56 |
| Boston Scientific Corp. | 3.28 |
| UnitedHealth Group, Inc. | 3.15 |
| Anthem, Inc. | 2.84 |
| AstraZeneca plc | 2.76 |
| Total Portfolio % | 37.61 |
| label | percentageholding |
|---|---|
| Abbott Laboratories | 5.13 |
| Medtronic plc | 4.68 |
| Pfizer, Inc. | 4.66 |
| Bristol-Myers Squibb Co. | 4.20 |
| Thermo Fisher Scientific, Inc. | 3.83 |
| Eli Lilly & Co. | 3.59 |
| Boston Scientific Corp. | 3.50 |
| Anthem, Inc. | 3.46 |
| Danaher Corp. | 3.15 |
| AstraZeneca plc | 2.93 |
| Total Portfolio % | 39.13 |
| Inception Date | 05/01/2000 |
| Symbol | HGHIX |
| CUSIP | 416649887 |
| Fund Number | 1309 |
Subsector Exposure
| label | currentpercentage |
|---|---|
| Medical Technology | 29 |
| Biopharma Large Cap | 23 |
| Health Care Services | 20 |
| Biopharma Mid Cap | 18 |
| Biopharma Small Cap | 9 |
| label | currentpercentage |
|---|---|
| Medical Technology | 32 |
| Biopharma Large Cap | 21 |
| Health Care Services | 18 |
| Biopharma Mid Cap | 18 |
| Biopharma Small Cap | 11 |
Healthy Skepticism: Is the Market Unfairly Punishing Healthcare Stocks?
05/15/2019
Investable Innovation: Tracking Remarkable Biopharmaceutical Advances
05/07/2019Financial Professionals:
Log in to order forms and literature and manage your subscriptions.
-
Add to favorite(0) -
Email(0) -
Add to Cart(0)
Fund LiteratureSelect All
0 items Selected
|
Fact Sheet12/31/2019 | pdfThis client flyer summarizes the Fund's investment approach, portfolio statistics, top holdings, and current performance. |
Fund Story09/30/2019 | pdfThis Fund Story outlines three distinguishing characteristics to help investors better understand the Fund. |
Commentary09/30/2019 | pdfCurrent quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund. |
Expanded Commentary09/30/2019 | pdfCurrent quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
|
Summary Prospectus03/01/2019 | pdfA concise summary of the Fund’s investment strategy, performance, expenses, risks, and management team.
|
Pitchbook09/30/2019 | pdfThis Pitchbook reviews the Funds' investment approach, investment team, investment process, and general portfolio parameters.
|
Semi Annual Report04/30/2019 | pdfA semi-annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.
|
Statutory Prospectus03/01/2019 | pdfAn annual update on the Fund that includes information about the Fund’s investment manager, sub-adviser, and operations.
|
Annual Report10/31/2019 | pdfAn annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.
|
SAI03/01/2019 | pdfA supplementary document to the Fund’s prospectus that includes additional information about the Fund and its operations.
|
1 The Morningstar Analyst Rating is not a credit or risk rating. It is a subjective evaluation performed by the manager research analysts of Morningstar. Morningstar evaluates funds based on five key pillars, which are process, performance, people, parent, and price. Analysts use this five pillar evaluation to determine how they believe funds are likely to perform over the long term on a risk-adjusted basis. They consider quantitative and qualitative factors in their research, and the weighting of each pillar may vary. The Analyst Rating scale is Gold, Silver, Bronze, Neutral, Negative. A Morningstar Analyst Rating of Gold, Silver, or Bronze reflects an Analyst’s conviction in a fund’s prospects for outperformance. Analyst Ratings are continuously monitored and reevaluated at least every 14 months. The Morningstar Analyst Rating should not be used as the sole basis in evaluating a mutual fund. Morningstar Analyst Ratings involve unknown risks and uncertainties which may cause Morningstar’s expectations not to occur or to differ significantly from what we expected. For more detailed information about Morningstar’s Analyst rating, including its methodology, please go to hartfordfunds.com/MorningstarAnalystMethodology.
212244 210715